CAS NO: | 129425-81-6 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
MSA-2是一种口服非核苷酸STING激动剂,对人的STING亚型WT和HAQ的EC50分别为8.3和24μM。MSA-2在同基因小鼠肿瘤模型中显示抗肿瘤活性,刺激肿瘤分泌干扰素-β,诱导肿瘤消退,具有持久的抗肿瘤免疫,并与抗PD-1协同作用。
Cas No. | 129425-81-6 |
Canonical SMILES | O=C(C1=CC(C(S1)=C2)=CC(OC)=C2OC)CCC(O)=O |
分子式 | C14H14O5S |
分子量 | 294.32 |
溶解度 | DMSO: 125 mg/mL (424.71 mM) |
储存条件 | 4°C, protect from light |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | MSA-2, a potent and orally available non-nucleotide STING agonist, has EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models[1]. MSA-2 dosed via either PO or SC regimens achieved comparable exposure in both tumor and plasma. MSA-2 also exhibits dose-dependent antitumor activity when administered by IT, SC, or PO routes, and dosing regimens were identified that induced complete tumor regressions in 80 to 100% of treated animals[1].MSA-2 (PO: 60 mg/kg or SC: 50 mg/kg; single dose) that effectively inhibits tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor[1]. Animal Model: MC38 tumor-bearing C57BL6 mice[1] [1]. Pan BS, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369(6506):eaba6098. |